NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Antheia

Antheia

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://antheia.bio/

Last Round

Series C

Extension

Jan 27, 2026

Total Funding Raised

$342M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Antheia is a biotechnology company that develops plant-inspired medicines using synthetic biology, informatics, and fermentation technology to create active pharmaceutical ingredients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Pharma Supply Chain, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Data as a Service

AI Layer

Application

Keywords

synthetic biologybiomanufacturingactive pharmaceutical ingredientsAPIkey starting materialsKSMpharma supply chainbiosynthesisdrug manufacturingonshoringmicrobial fermentationstrain engineeringCDMObio-based manufacturingsynthetic pharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Antheia Comparables

Compare Antheia with similar companies based on industry and business-model similarity.

Antheia comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Fermelanta, Inc.
71%
Codexis
71%
Ginkgo Bioworks
67%

Antheia Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionJan 27, 2026
Series CJun 3, 2025
GrantDec 3, 2024
GrantJul 19, 2024
Series CJan 24, 2024
Debt
Jun 22, 2022

Key People

Founding team and executive leadership

Christina Smolke

CEO Co-Founder

Founding Team

Eric d'Esparbes

Chief Financial Officer

Executive Team

Zack McGahey

Chief Operating Officer

Executive Team

Antheia Investors

Notable investors and investment history

Antheia investors
InvestorRounds
Sherpalo VenturesSeries C Extension, Series C, Series B
America's Frontier FundSeries C Extension
AFFSeries C Extension
Athos KGSeries C, Series C Extension
EDBISeries C Extension, Series C
S-Cubed CapitalSeries C Extension, Series C
Public Health Emergency Medical Countermeasures EnterpriseGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Added Contract Pharma, a media/publishing SMB, as a customer.

  • Jan 27, 2026

    $80M Series C round completed.

Antheia Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Antheia Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Antheia's valuation, stock price, and market status.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range66
Year Founded2013
Last FundingJan 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.